🔎 Trials Near Me

Nyumbani › Limfoma › Texas

Majaribio ya kliniki ya Limfoma katika jimbo la Texas

Masomo 45 ya Limfoma yanatafuta washiriki katika vituo vya jimbo la Texas.

Miji katika jimbo la Texas

Maandishi rasmi ya utafiti (Kiingereza)

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

  • Houston Methodist Hospital, Houston
  • Texas Children's Hospital, Houston
InaajiriHatua 1
Umri 12 hadi 75 · Jinsia zote · Imesasishwa 2 Okt 2026 · NCT02917083

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

  • Baylor Scott & White Research Institute, Texas Oncology, Dallas
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 1 Okt 2026 · NCT06343311

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Texas Children's Hospital, Houston
InaajiriUtafiti wa uchunguzi
Umri 0 hadi 38 · Jinsia zote · Imesasishwa 1 Okt 2026 · NCT06131801

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

  • The University of Texas - MD Anderson Cancer Center, Houston
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 30 Sep 2026 · NCT07192471

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

  • MD Anderson Cancer Center, Houston
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 30 Sep 2026 · NCT07015242

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  • The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
  • Baylor College of Medicine, Houston
InaajiriHatua 1/2
Hadi umri 25 · Jinsia zote · Imesasishwa 25 Sep 2026 · NCT04094610

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

  • University of Texas - MD Anderson Cancer Center, Houston
InaajiriHatua 1
24 Months – 18 Years · Jinsia zote · Imesasishwa 25 Sep 2026 · NCT06441331

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • Texas Oncology - Center South, Austin
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 17 Sep 2026 · NCT07221500

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

  • Sarah Cannon Research Institute at St. David's South Austin, Austin
InaajiriHatua 1
Umri 18 hadi 100 · Jinsia zote · Imesasishwa 15 Sep 2026 · NCT05798897

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  • Research Site, Houston
InaajiriHatua 1/2
Umri 12 na zaidi · Jinsia zote · Imesasishwa 14 Sep 2026 · NCT06137144

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • Cook Children's Medical Center, Fort Worth
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
InaajiriHatua 1/2
12 Months – 21 Years · Jinsia zote · Imesasishwa 11 Sep 2026 · NCT04870944

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Baylor College of Medicine, Houston
  • Renovatio Clinical, The Woodlands
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 8 Sep 2026 · NCT06624085

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

  • The University of Texas MD Anderson Cancer Center, Houston
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 4 Sep 2026 · NCT07082803

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  • Renovatio Clinical - El Paso, El Paso
  • Renovatio Clinical, The Woodlands
InaajiriHatua 3
Umri 18 na zaidi · Jinsia zote · Imesasishwa 3 Sep 2026 · NCT06084936

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • Baylor Scott & White Health, Dallas
  • MD Anderson, Houston
InaajiriHatua 1/2
Umri 12 na zaidi · Jinsia zote · Imesasishwa 3 Sep 2026 · NCT04588922

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

  • MD Anderson Cancer Center, Houston
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 28 Ago 2026 · NCT07284433

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Baylor University Medical Center, Dallas
  • Texas Transplant Institute, San Antonio
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 25 Ago 2026 · NCT05826535

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

  • MD Anderson Cancer Center, Houston
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 17 Ago 2026 · NCT06218602

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • University of Texas MD Anderson Cancer Center, Houston
InaajiriHatua 1/2
Umri 13 hadi 90 · Jinsia zote · Imesasishwa 6 Ago 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • St. David's South Austin Medical Center, Austin
  • University of Texas Southwestern Medical Center, Fort Worth
  • MD Anderson Cancer Center, Houston
  • na zaidi ya 1
InaajiriHatua 3
Umri 18 na zaidi · Jinsia zote · Imesasishwa 4 Ago 2026 · NCT07188558

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

  • The University of Texas M D Anderson Cancer Center, Houston
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 29 Jul 2026 · NCT05773040

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

  • MD Anderson Cancer Center, Houston
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 24 Jul 2026 · NCT06563505

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

  • MD Anderson Cancer Center, Houston
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 16 Jul 2026 · NCT05929612

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

  • MD Anderson Cancer Center, Houston
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 15 Jul 2026 · NCT05464719

DALY II USA/ MB-CART2019.1 for DLBCL

  • UT Southwestern Medical Center, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
  • Texas Transplant Institute, San Antonio
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 13 Jul 2026 · NCT04792489

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

  • MD Anderson, Houston
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 8 Jul 2026 · NCT07465835

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  • Call for Information (Investigational Site 0054), Dallas
InaajiriHatua 1/2
6 Months – 17 Years · Jinsia zote · Imesasishwa 6 Jul 2026 · NCT02332668

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • MD Anderson Cancer Center, Houston
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 2 Jul 2026 · NCT05131022

CD4CAR for CD4+ Leukemia and Lymphoma

  • The University of Texas MD Anderson Cancer Center, Houston
InaajiriHatua 1
Umri 12 na zaidi · Jinsia zote · Imesasishwa 24 Jun 2026 · NCT03829540

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site, Houston
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 17 Jun 2026 · NCT05475925

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

  • M D Anderson Cancer Center, Houston
InaajiriUtafiti wa uchunguzi
Umri 18 na zaidi · Jinsia zote · Imesasishwa 20 Mei 2026 · NCT05011045

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

  • MD Anderson Cancer Center, Houston
  • Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio
Inaajiri
Umri 18 na zaidi · Jinsia zote · Imesasishwa 20 Mei 2026 · NCT05676450

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • University of Texas Health Science Center at San Antonio, San Antonio
InaajiriUtafiti wa uchunguzi
Umri wote · Jinsia zote · Imesasishwa 18 Mei 2026 · NCT01790152

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • The University of Texas MD Anderson Cancer Center, Houston
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 16 Apr 2026 · NCT03328078

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • University of Texas(UT) Southwestern-Children's Medical Center, Dallas
InaajiriHatua 1/2
Umri 12 hadi 95 · Jinsia zote · Imesasishwa 15 Apr 2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • MD Anderson Cancer Center, Houston
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 20 Mac 2026 · NCT04830137

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

  • Harris Health System (includes ben Taub General Hospital and Smith), Houston
  • Houston Methodist Hospital, Houston
  • Texas Children's Hospital, Houston
InaajiriHatua 1
Umri wote · Jinsia zote · Imesasishwa 2 Mac 2026 · NCT01555892

Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.